Evaluation of a patient decision aid for BRCA1/2 pathogenic variant carriers choosing an ovarian cancer prevention strategy.

Saved in:
Bibliographic Details
Title: Evaluation of a patient decision aid for BRCA1/2 pathogenic variant carriers choosing an ovarian cancer prevention strategy.
Authors: Steenbeek MP; Radboud University Medical Center, Radboud Institute for Health Sciences, Department of Obstetrics and Gynecology, Nijmegen, the Netherlands., van Bommel MHD; Radboud University Medical Center, Radboud Institute for Health Sciences, Department of Obstetrics and Gynecology, Nijmegen, the Netherlands. Electronic address: Majke.vanBommel@radboudumc.nl., Harmsen MG; Radboud University Medical Center, Radboud Institute for Health Sciences, Department of Obstetrics and Gynecology, Nijmegen, the Netherlands., Hoogerbrugge N; Radboud University Medical Center, Department of Human Genetics, PO Box 9101, 6500, HB, Nijmegen, the Netherlands., van Doorn HC; Department of Gynecology, Erasmus MC Cancer Clinic, 's, Gravendijkwal 230, 3015, CE, Rotterdam, the Netherlands., Keurentjes JHM; Department of Gynecologic Oncology, University of Groningen, University Medical Centre Groningen, Hanzeplein 1, 9713, GZ, Groningen, the Netherlands., van Beurden M; Centre for Gynecological Oncology Amsterdam (CGOA), Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066, CX, Amsterdam, the Netherlands., Zweemer RP; Department of Gynecological Oncology, UMC Utrecht Cancer Centre, Heidelberglaan 100, 3584, CX, Utrecht, the Netherlands., Gaarenstroom KN; Department of Obstetrics and Gynecology, Leiden University Medical Centre, Albinusdreef 2, 2333, ZA, Leiden, the Netherlands., Penders CGJ; Department of Obstetrics and Gynecology, Maastricht University Medical Centre, GROW-School for Oncology and Developmental Biology, P. Debyelaan 25, 6229 HX Maastricht, the Netherlands., Brood-van Zanten MMA; Department of Obstetrics and Gynaecology, Amsterdam UMC, Meibergdreef 9, 1105, AZ, Amsterdam, the Netherlands; Department of Obstetrics and Gynecology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066, CX, Amsterdam, the Netherlands., Vos MC; Gynecologic Oncologic Centre South location Elisabeth-TweeSteden Hospital, Hilvarenbeekseweg 60, 5000, LC, Tilburg, the Netherlands., Piek JM; Gynecologic Oncologic Centre South location Catharina Hospital, Michelangelolaan 2, 5623 EJ Eindhoven, the Netherlands., van Lonkhuijzen LRCW; Department of Obstetrics and Gynaecology, Amsterdam UMC, Meibergdreef 9, 1105, AZ, Amsterdam, the Netherlands., Apperloo MJA; Department of Obstetrics and Gynecology, Medical Centre Leeuwarden, Henri Dunantweg 2, 8934, AD, Leeuwarden, the Netherlands., Coppus SFPJ; Department of Obstetrics and Gynecology, Maxima Medical Centre, De Run 4600, 5504, DB, Veldhoven, the Netherlands., IntHout J; Radboud University Medical Center, Radboud Institute for Health Sciences, Department for Health Evidence, PO Box 9101, 6500, HB, Nijmegen, the Netherlands., de Hullu JA; Radboud University Medical Center, Radboud Institute for Health Sciences, Department of Obstetrics and Gynecology, Nijmegen, the Netherlands., Hermens RPMG; Radboud University Medical Center, Scientific Institute for Quality of Healthcare, PO Box 9101, 6500, HB, Nijmegen, the Netherlands.
Source: Gynecologic oncology [Gynecol Oncol] 2021 Nov; Vol. 163 (2), pp. 371-377. Date of Electronic Publication: 2021 Aug 27.
Publication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Academic Press Country of Publication: United States NLM ID: 0365304 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1095-6859 (Electronic) Linking ISSN: 00908258 NLM ISO Abbreviation: Gynecol Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1095-6859
DOI:10.1016/j.ygyno.2021.08.019